NEW YORK (GenomeWeb) – HaploX Biotechnology, a Shenzhen, China-based company focused on precision medicine and genetic data, has closed a $32 million Series A-plus financing round.

Participants in the round included SB China Venture Capital (SBCVC) and Kexin Capital, HaploX CEO and Founder Mingyan Xu said in an email. SBCVC previously led HaploX's 2016 Series A financing, which raised approximately $10 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.

Jun
12
Sponsored by
Philips Genomics

This webinar will highlight a comprehensive end-to-end solution for precision care in oncology, comprising sample acquisition through to sequencing and analysis, treatment recommendations, and follow-through.